post-1

Lobe Sciences Retains Jolt Communications to Increase Investor Awareness

Lobe Sciences Retains Jolt Communications to Increase Investor Awareness

post-1

Meet Lobe Sciences A Life Sciences Company Focused on Psychedelic Medicines

Meet Lobe Sciences A Life Sciences Company Focused on Psychedelic Medicines

post-1

Lobe Sciences Announces Pending Patents and Preclinical Research Studies

Lobe Sciences Announces Pending Patents and Preclinical Research Studies

post-1

Lobe Sciences Announces Management Changes and New Director

Appointment of Philip Young as CEO and director adds a seasoned executive with a track record of new device and therapeutics development, FDA/regulatory approvals, capital markets, M&A and operational success

post-1

Lobe Sciences Announces Changes to Board of Directors

Appointment of Michael Petter to the Board brings another seasoned board member with strong industry, capital markets and strategic planning expertise.

post-1

Lobe Sciences Announces Jonathan Gilbert Appointed Executive Chairman of the Board of Directors

Appointment of Jonathan Gilbert as Executive Chairman allows Lobe to capitalize on his significant capital markets experience

post-1

Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.

Signed LOI for CAD$23 million sale to Ionic provides shareholder value

post-1

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine